Data investigation

Real, and Below the Threshold

Semaglutide improves patient-reported physical functioning by 1.71 points, with an interval excluding zero. The threshold at which a patient notices a change is 3.7 points. Both are true at once.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
6 min read·1 citation

Semaglutide improves patient-reported physical functioning. The improvement is 1.71 points, with a confidence interval from 1.07 to 2.35 that comfortably excludes zero, so it is real. The threshold at which a patient would notice a change is 3.7 points.[1] Both are true at once, and the gap between them is the difference between statistical and clinical significance.

Two different bars

Statistical significance asks whether an effect is distinguishable from chance. Clinical significance asks whether it is large enough to matter to the person experiencing it. They are separate questions with separate answers, and a result can clear one bar and fail the other.

Here, the meaningful within-patient change threshold is a number researchers establish in advance, by asking patients how much a score has to shift before they perceive a difference. For this instrument it is 3.7 points. The drug delivers 1.71.

Physical functioning improved by 1.71 points, less than half the 3.7 points at which patients notice a change.

The same pattern held on a second, weight-specific instrument across two trials and 2,768 participants: larger effects in people without type 2 diabetes, smaller in people with it, and both below the published thresholds.

The picture this completes

Two earlier studies we have covered arrived at the same place by different routes, and this review makes the third. A fourth, in heart failure, found the opposite.

What the evidence says about quality of life on these drugs.
SourceFinding
Network meta-analysis of 262 trialsNo drug improved quality of life beyond the threshold, across 43 trials and 45,663 participants
The head-to-head trialThe mental component improved in neither arm over 72 weeks
This reviewPhysical functioning improved statistically, and below the threshold patients notice
The two heart failure trialsCleared the threshold — +7.8 and +6.9 points against a bar of about 5
The last row is what resolves the other three. The heart failure trials used a questionnaire built from the symptoms of one disease, in people who have that disease and whose drug treats it. The others used general health surveys, which average across everything in a life. A specific instrument in the right disease finds what a general one dilutes to nothing.

So the supportable claim is narrow and consistent: there is no good evidence these drugs make people feel better in general, and there is good evidence they relieve the symptoms of specific conditions they treat.

Who ran every one of these trials

The authors state it directly: the available randomized evidence comes from the semaglutide development program. Every trial in this analysis belongs to the manufacturer. There is no independent randomized evidence at all, conflicting or otherwise, on what these drugs do to quality of life.

That matters less than it might, because the finding is a modest one. A sponsor’s own trials reporting an improvement smaller than patients would notice is not the direction bias usually runs. If anything, it makes the result more credible than a larger one from the same source would be.

Heterogeneity was moderate at 52.8%, which is unremarkable for a pooled analysis but worth keeping in mind alongside the narrow confidence interval.

What to do with it

  • Physical improvement may be larger if you lose more weight, but this review did not test that link, and its average gain was below what patients notice.
  • Do not plan on feeling better in general. If that is the main reason for starting, this is the evidence to weigh, and it is not encouraging.
  • The exception is real and specific. In obesity-related heart failure, these drugs relieve the symptoms of that condition by an amount patients notice.
  • “Statistically significant” is not a synonym for “you will feel it.” When a paper reports an improvement, look for whether it names a threshold and whether the effect cleared it.

The authors’ own conclusion is that the gains are modest and should be communicated cautiously. That is an unusually plain thing for a paper to say about a positive finding, and it is the right instruction.

Frequently Asked Questions

It improves patient-reported physical functioning by 1.71 points, with a confidence interval excluding zero, so the effect is real. The threshold at which patients perceive a change on that instrument is 3.7 points, so it falls below what someone would notice.
Statistical significance asks whether an effect is distinguishable from chance. Clinical significance asks whether it is big enough for the person to feel. A large, well-conducted analysis can establish a small effect very precisely, and this is that case.
Effects were larger in people without type 2 diabetes and smaller in those with it, and both remained below the published thresholds on a second weight-specific instrument.
Yes, in a specific case. In obesity-related heart failure, trials using a questionnaire built from that condition's symptoms found improvements of 7.8 and 6.9 points against a threshold of about 5. That is a disease-specific instrument in a disease the drug treats.
All of them come from the semaglutide development program, as the authors state. There is no independent randomized evidence on quality of life with these drugs. That matters less than usual here, since a sponsor reporting an effect smaller than patients would notice is not the direction bias normally runs.

References

  1. 1.Eisa N, Khoury M. The Effect of Semaglutide on Quality of Life in Adults With Overweight or Obesity: A Brief Systematic Review and Meta-Analysis Diabetes, Obesity and Metabolism. 2026. PMID: 42297754.

The Mental Health Score That Did Not Move

In the head-to-head trial, physical quality-of-life scores improved clearly over 72 weeks. The Mental Component Summary did not significantly improve in either arm, a result the paper's own conclusion omits.

6 min read

Judged Worse Than Not Losing Weight

Researchers gave 607 people identical descriptions of a stranger, varying only how they had lost weight. The version who used a GLP-1 was judged more harshly than the version who had not lost weight at all.

6 min read

A Quarter the Odds of Being Offered It

People with diabetes who also have a mental health diagnosis received worse care on almost every measure, and a quarter of the odds of being prescribed a GLP-1, while having half again the odds of being put on insulin.

7 min read

Antipsychotics and Metabolic Harm

The drugs that work best for schizophrenia are the hardest on metabolism, and switching is often not an option. A Danish trial treated the consequence instead, and measured psychiatric symptoms as an outcome.

7 min read

Eight Things Patients Said

Trials measure weight and adverse events. They do not measure being judged for taking a drug. Researchers interviewed 30 people across 15 states and sorted what they said into eight themes.

6 min read

Does Ozempic or Mounjaro Cause Anxiety? What the Trials and Labels Show

In randomized trials, anxiety was no more common on semaglutide or tirzepatide than on placebo. Where cohort studies and adverse-event reports disagree, why low blood sugar and a faster pulse can feel like anxiety, and what is known about panic attacks.

12 min read

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

8.2

HealthRX

Compounded semaglutide at $165/month after a $99 first month

8.2

bmiMD

Starting below a standard dose, with microdose tiers

9.0

YourEra

Semaglutide at $99/month, well below the typical price

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →